Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat Tumors
Atomwise Partners with Global Research Teams to Pursue Broad-Spectrum Treatments Against COVID-19 and Future Coronavirus Outbreaks
WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in the United States
Sherlock Biosciences Launches Innovation Lab to Develop COVID-19 Diagnostics with $7.5 Million Grant from Open Philanthropy
